PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27302463-0	2016	Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma.	Sorafenib	61-70	distal-less homeobox 2	Homo sapiens	18-22	
27302463-6	2016	Moreover, the sensitivity of HCC cells to sorafenib is restored when the DLX2 gene is knocked down using a short interfering RNA.	Sorafenib	42-51	distal-less homeobox 2	Homo sapiens	73-77	
27302463-7	2016	We demonstrated that DLX2 facilitates sorafenib resistance by promoting the expression of markers of epithelial-mesenchymal transition and by activating the extracellular signal-regulated protein kinase pathway.	Sorafenib	38-47	distal-less homeobox 2	Homo sapiens	21-25	
27302463-8	2016	Our findings reveal that DLX2 plays a regulatory role in HCC cell proliferation and suggests that targeting DLX2 represents a novel strategy to increase sorafenib efficacy in the management of HCC.	Sorafenib	153-162	distal-less homeobox 2	Homo sapiens	25-29	
27302463-8	2016	Our findings reveal that DLX2 plays a regulatory role in HCC cell proliferation and suggests that targeting DLX2 represents a novel strategy to increase sorafenib efficacy in the management of HCC.	Sorafenib	153-162	distal-less homeobox 2	Homo sapiens	108-112	
27302463-9	2016	In conclusion, DLX2 is a novel marker of poor prognosis and sorafenib resistance in patients with HCC.	Sorafenib	60-69	distal-less homeobox 2	Homo sapiens	15-19